TriangleNCT02039947 · OUTCOME
Progression-free Survival (PFS) for Each Cohort Based on Investigator Assessment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Month
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the first dose to the earliest date of disease progression or death
What was measured
PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause. No hypothesis testing completed for cohort A,B,C and D
Analysis population: All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population
Groups in this outcome
Cohort A
Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
Cohort B
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
Cohort C
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
Cohort D
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
| Group | Source count |
|---|---|
| Cohort A | 76 |
| Cohort B | 16 |
| Cohort C | 16 |
| Cohort D | 17 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A | 5.7 | Not reported | 5.3 | 7.3 | Not reported |
| Cohort B | 7.2 | Not reported | 4.7 | 14.6 | Not reported |
| Cohort C | 3.7 | Not reported | 1.7 | 6.5 | Not reported |
| Cohort D | 5.5 | Not reported | 3.7 | 11.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.3
- upper Limit
- 7.3
- value
- 5.7
- group Id
- OG001
- lower Limit
- 4.7
- upper Limit
- 14.6
- value
- 7.2
- group Id
- OG002
- lower Limit
- 1.7
- upper Limit
- 6.5
- value
- 3.7
- group Id
- OG003
- lower Limit
- 3.7
- upper Limit
- 11.6
- value
- 5.5
- denoms
- counts
- group Id
- OG000
- value
- 76
- group Id
- OG001
- value
- 16
- group Id
- OG002
- value
- 16
- group Id
- OG003
- value
- 17
- units
- Participants
- description
- PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause. No hypothesis testing completed for cohort A,B,C and D
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
- id
- OG000
- title
- Cohort A
- description
- Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- id
- OG001
- title
- Cohort B
- description
- Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- id
- OG002
- title
- Cohort C
- description
- Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- id
- OG003
- title
- Cohort D
- param Type
- MEDIAN
- population Description
- All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population
- reporting Status
- POSTED
- time Frame
- From the first dose to the earliest date of disease progression or death
- title
- Progression-free Survival (PFS) for Each Cohort Based on Investigator Assessment
- type
- SECONDARY
- unit Of Measure
- Month
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice